|Articles|May 1, 2012
- Pharmaceutical Executive-05-01-2012
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - May 2012
Marooned at the Top
Advertisement
Articles in this issue
about 14 years ago
Pharma 50 Comment: Seeding Beyond the Baseabout 14 years ago
Value-Based Pricing: Too High a Price for UK Pharma?about 14 years ago
Pharm Exec 50: Growth from the Bottom Upabout 14 years ago
Country Report: South Africaabout 14 years ago
Managing Information Overloadabout 14 years ago
Super-Size Me: Optimizing the Information Explosionabout 14 years ago
Government: Big Pharma's Best Friend in Emerging Markets?about 14 years ago
Information Overloadabout 14 years ago
Pharma's Winning Innovative TechnologyAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 million Series A
2
FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010
3
Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010
4
Additive Manufacturing's Application in Pharma and Biotech
5